Mettler-Toledo International Inc. (MTD) fair value analysis
S&P 500 · Updated 2026-10-19
MTD price how computed
Forward Fair Value verdict
Fairly valuedMTD is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $1,549.99
- Sector
- Healthcare
- 12-month range
- $1,025.53–$1,639.04
- Market cap
- $31.1B
- From 52-week high
- -5.4%
- Shares outstanding
- 20M
- Rank in Healthcare by discount to fair value
- #52 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Mettler-Toledo International Inc. manufactures and sells precision instruments and services for laboratory, industrial, and retail applications, including analytical balances, pipettes, thermal analysis equipment, and software solutions. The company operates globally across North America, Europe, Asia, and other international markets.
MTD currently ranks #52 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $31.1B
- P/E (trailing)
- 35x
- Revenue (TTM)
- $4.13B
- Net margin
- 21.9%
- EPS (TTM)
- $44.88
- Gross margin
- 63.3%
- Debt / equity
- 164.70
- Revenue growth (3-yr avg)
- 3.0%
- Shares outstanding
- 20M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 74 · overbought
- 50-day average
- $1,443.62
- 200-day average
- $1,326.89
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-05 (post-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.3%)
2026-03 ▲ beat (+2.3%)
2025-12 ▲ beat (+4.3%)
2025-09 ▲ beat (+4.6%)
2025-06 ▲ beat (+5.1%)
2025-03 ▲ beat (+3.9%)
2024-12 ▲ beat (+5.9%)
2024-09 ▲ beat (+2.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 7 hold · 2 sell (14 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $1530
- Target vs last price
- -1.3%
What our data shows for MTD
- Our model validated 17 trailing price-to-earnings windows for MTD, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $1,025.53–$1,639.04.
- The 14-day relative strength index sits at an overbought 74.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for MTD
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MTD news
TickrTrends' derived news-sentiment signal for MTD is currently leaning positive, computed from recent coverage.
- MTD Maintains by Morgan Stanley -- Price Target Raised to $1575 (gurufocus.com, 2026-10-13)
TickrTrends take: Morgan Stanley's raise of MTD's price target to 1575 aligns with the stock's current Fairly valued assessment under TickrTrends analysis. For investors focused on valuation metrics, the maintained rating suggests analyst confidence is not translating into a major directional shift, meaning current pricing may already reflect the analyst's optimistic view of the company's prospects. Monitoring whether MTD's operational performance in the Healthcare sector can sustain this valuation level will be key for determining whether the Fairly valued designation holds. - Shares Of Mettler-Toledo International Are Still Too Pricey For My Liking (NYSE:MTD) (seekingalpha.com, 2026-10-09)
TickrTrends take: Mettler-Toledo International operates in the Healthcare sector and currently carries a TickrTrends valuation assessment of Fairly valued, which suggests the market is pricing in reasonable expectations for the company's fundamentals. An analyst has expressed concern that shares remain too expensive despite this assessment, indicating that valuation-focused investors may want to monitor whether the company's earnings growth or operational performance can justify current price levels. Readers should watch for updates on MTD's profitability metrics and revenue trends to determine if the Fairly valued designation will hold or shift in coming quarters. - A Look at Mettler-Toledo International Inc (MTD) After 3.7% Gain -- GF Value $1446.01 vs Price $1541.63 (gurufocus.com, 2026-10-05)
TickrTrends take: Mettler-Toledo International Inc trades above its GF Value estimate, suggesting the stock is priced at a premium to this particular valuation model's assessment. The Healthcare sector company's current TickrTrends verdict of fairly valued indicates the market pricing reflects reasonable expectations about the business, despite the gap between the valuation benchmark and the trading price. Investors focused on valuation metrics should monitor whether this premium persists or narrows as earnings and market conditions evolve.
What people are saying
Follow the MTD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for the Healthcare sector MTD show a shift in momentum this week, with the RSI zone moving from neutral into overbought territory. The sector maintains a fairly valued designation based on current valuation metrics. This technical movement suggests increased buying pressure within Healthcare equities over the past week.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for the Healthcare sector showed a decline in valuation competitiveness this week, with the sector discount rank moving from number 44 to number 51. Despite this downward shift in ranking, the Healthcare sector maintains an undervalued status according to current valuation metrics. The sector's weaker relative position suggests it has become less attractively valued compared to other sectors within the market.
- 2026-09-21 — TickrTrends' derived indicators for the Healthcare sector MTD show a shift in the Relative Strength Index from oversold to neutral territory this week. The sector's current valuation verdict remains Undervalued based on the available technical assessment.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MTD stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), MTD is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is MTD's TickrTrends verdict?
MTD's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does MTD compare to other Healthcare stocks?
MTD ranks #52 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is MTD overbought or oversold?
MTD's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
When does MTD report earnings next?
MTD's next earnings report is scheduled for 2026-11-05 (post-market), per the published earnings calendar.
Does MTD usually beat earnings estimates?
Over its last 8 reported quarters MTD beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MTD?
Of 14 analysts covering MTD, 5 rate it a buy, 7 a hold and 2 a sell - hold-leaning, with a consensus price target of $1530 (-1.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
MTD vs DHR · MTD vs EXEL · MTD vs HCA · MTD vs HCSG · MTD vs IQV